EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 30 / Numéro 3 (Mars 2014) Med Sci (Paris), 30 3 (2014) 303-310 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 3, Mars 2014
Page(s) 303 - 310
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143003019
Publié en ligne 31 mars 2014
  1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002 ; 346 : 1773–1780. [CrossRef] [PubMed] [Google Scholar]
  2. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004 ; 350 : 221–231. [CrossRef] [PubMed] [Google Scholar]
  3. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007 ; 370 : 937–948. [CrossRef] [PubMed] [Google Scholar]
  4. Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012 ; 125 : 1110–1121. [CrossRef] [PubMed] [Google Scholar]
  5. Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012 ; 125 : 584–591. [CrossRef] [PubMed] [Google Scholar]
  6. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007 ; 115 : 2426–2434. [CrossRef] [PubMed] [Google Scholar]
  7. Hassan AK, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2010 ; 31 : 1172–1180. [CrossRef] [PubMed] [Google Scholar]
  8. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by Stent design and deployment and protected by polymer-drug coatings. Circulation 2011 ; 123 : 1400–1409. [CrossRef] [PubMed] [Google Scholar]
  9. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting Stent on Stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011 ; 58 : 1569–1577. [CrossRef] [PubMed] [Google Scholar]
  10. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary Stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012 ; 125 : 2873–2891. [CrossRef] [PubMed] [Google Scholar]
  11. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting Stent with biodegradable polymer versus sirolimus-eluting Stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008 ; 372 : 1163–1173. [CrossRef] [PubMed] [Google Scholar]
  12. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting Stents versus durable polymer sirolimus-eluting Stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011 ; 378 : 1940–1948. [CrossRef] [PubMed] [Google Scholar]
  13. Nishio S, Kosuga K, Igaki K, et al. Long-term (> 10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary Stents: Igaki-Tamai Stents. Circulation 2012 ; 125 : 2343–2353. [CrossRef] [PubMed] [Google Scholar]
  14. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary Stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008 ; 371 : 899–907. [CrossRef] [PubMed] [Google Scholar]
  15. Okamura T, Garg S, Gutierrez-Chico JL, et al. In vivo evaluation of Stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 Stent design in the ABSORB clinical trial. EuroIntervention 2010 ; 5 : 932–938. [CrossRef] [PubMed] [Google Scholar]
  16. Waksman R. Current state of the absorbable metallic (magnesium) Stent. EuroIntervention 2009 ; 5 (suppl F) : F94–F97. [CrossRef] [PubMed] [Google Scholar]
  17. Lafont A, Durand E. ART: concept of a bioresorbable Stent without drug elution. EuroIntervention 2009 ; 5 (suppl F) : F83–F87. [CrossRef] [PubMed] [Google Scholar]
  18. Durand E, Lemitre M, Couty L, et al. Adjusting a polymer formulation for an optimal bioresorbable Stent: a 6-month follow-up study. EuroIntervention 2012 ; 8 : 242–249. [CrossRef] [PubMed] [Google Scholar]
  19. Jabara R, Pendyala L, Geva S, et al. Novel fully bioabsorbable salicylate-based sirolimus-eluting Stent. EuroIntervention 2009 ; 5 (suppl F) : F58–64. [CrossRef] [PubMed] [Google Scholar]
  20. Van Geuns RJ, Tamburino C, Fajadet J, et al. Self-expanding versus balloon-expandable Stents in acute myocardial infarction: results from the APPOSITION II study: self-expanding Stents in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2012 ; 5 : 1209–1219. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.